Economics at the FTC: Pharmaceutical patent dispute settlements and behavioral economics

Review of Industrial Organization

Volumn 31, Issue 2, 2007, Pages 85-105

  Salinger, Michael A ^a   Ippolito, Pauline M ^a   Schrag, Joel L ^a  

^a FEDERAL TRADE COMMISSION   (United States)

Author keywords

Antitrust; Behavioral economics; Consumer protection; FTC; Patents; Pharmaceuticals

Indexed keywords

COMPETITION (ECONOMICS); CONSUMPTION BEHAVIOR; PHARMACEUTICAL INDUSTRY;

EID: 36649023134     PISSN: 0889938X     EISSN: 15737160     Source Type: Journal    
DOI: 10.1007/s11151-007-9151-y     Document Type: Article

References (33)

1. Agarwal S., Driscoll J.C., Gabaix X., Laibson D. (2006). Stimulus and response: The path from naivete to sophistication in the credit card market. Mimeo, Harvard University
2. Barberis N.C., Thaler R. (2003). A survey of behavioral finance. In: Constantinides G., Harris M., Stulz R.(eds) Handbook of the economics of finance. North Holland, Elsevier, pp. 1052-1090
3. Beales J.H., III. (2003). The Federal Trade Commission's use of unfairness authority: Its rise, fall, and resurrection. Journal of Public Policy & Marketing 22(2): 192-200
4. Camerer, C. F. (2007). Behavioral economics. In Advances in economics and econometrics, theory and applications, Ninth World Congress, (Vol.2). R. Blundell, W. Newey, & T. Persson (Eds.), New York: Cambridge University Press.
5. Camerer C.F., Issacharoff S., Loewenstein G., O'Donoghue T., Rabin M. (2003). Regulation for conservatives: Behavioral economics and the case for asymmetric paternalism. University of Pennsylvania Law Review 151(6): 1211-1254
6. Caves, R. E., Whinston, M. D., & Hurwitz, M. (1991). Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity: Microeconomics. pp. 1-66.
7. Diamond P., Vartiainen H. (2007). Behavioral economics and its application. Princeton, Princeton University Press
8. Ellison S., Cockburn I., Griliches Z., Hausman J.A. (1997). Characteristics of demand for pharmaceutical products: An examination of four cephalosporins. RAND Journal of Economics 28(3): 426-446
9. Federal Trade Commission. (2002). Generic drug entry prior to patent expiration: An FTC study. Washington: Federal Trade Commission. This study is available online at http://www.ftc.gov/os/2002/07/ genericdrugstudy.pdf. Accessed 30 Oct 2007.
10. Frank R., Salkever D. (1997). Generic entry and the pricing of pharmaceuticals. Journal of Economics & Management Strategy 6(1): 75-90
11. Gabaix X., Laibson D.I. (2006). Shrouded attributes, consumer myopia, and information suppression in competitive markets. Quarterly Journal of Economics 121(2): 505-540
12. Grabowski H.G., Vernon J.M. (1992). Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 35(2): 331-350
13. Grabowski H.G., Vernon J.M. (1996). Longer patents for increased generic competition in the US: The Waxman-Hatch Act after one decade. Pharmacoeconomics 10(2): 110-123
14. Ho T.H., Lim N., Camerer C.F. (2006). Modeling the psychology of consumer and firm behavior with behavioral economics. Journal of Marketing Research 15(3): 307-331
15. Ippolito P.M., Mathios A.D. (1990). Information, advertising and health choices: A study of the cereal market. RAND Journal of Economics 21(3): 459-480
16. Ippolito, P. M., & Mathios, A. D. (1996). Information and advertising policy, a study of fat and cholesterol consumption in the United States, 1977-1990. Bureau of Economics Staff Report, Federal Trade Commission, Washington, DC.
17. Ippolito, P. M., & Pappalardo, J. K. (2002). Advertising nutrition & health, evidence from food advertising 1977-1997. Bureau of Economics Staff Report, Federal Trade Commission, Washington, DC.
18. Kahneman D. (2003). Maps of bounded rationality: Psychology for behavioral economics. American Economic Review 93(5): 1449-1475
19. Kahneman D., Tversky A. (1979). Prospect theory: An analysis of decision under risk. Econometrica 47(2): 263-291
20. Lacko, J. M., & Pappalardo, J. K. (2004). The effect of mortgage broker compensation disclosures on consumers and competition: A controlled experiment. Bureau of Economics Staff Report, Federal Trade Commission, Washington, DC.
21. Lacko, J. M., & Pappalardo, J. K. (2007). Improving consumer mortgage disclosures, an empirical assessment of current and prototype disclosure forms. Bureau of Economics Staff Report, Federal Trade Commission, Washington, DC.
22. Laibson D.I. (1997). Golden eggs and hyperbolic discounting. Quarterly Journal of Economics 112(2): 443-477
23. Lemley M.A., Shapiro C. (2005). Probabilistic patents. Journal of Economic Perspectives 19(2): 75-98
24. Masson, A., & Steiner, R. (1985). Generic substitution and prescription drug prices: Economic effects of state drug product selection laws. Bureau of Economics Staff Report, Federal Trade Commission, Washington, DC.
25. McAuley, I. (2006). Roundtable on demand-side economics for consumer policy: Summary report. Report No. DSTI/CP(2006)3/FINAL. Directorate for Science, Technology and Industry, Committee on Consumer Policy, Organisation for Economic Co-operation and Development, Paris, France.
26. Miravete, E. (2007). Rational attention in a repeated decision problem. Paper presented at the Federal Trade Commission's conference on behavioral economics and consumer policy, Washington, DC.
27. Murphy, R. D., Hoppock, T., & Rusk, M. (1998). A generic copy test of food health claims in advertising. Bureau of Economics Staff Report, Federal Trade Commission, Washington, DC.
28. Murphy, R. D., Ippolito, P. M., & Pappalardo, J. K. (2007). Consumer perceptions of heart-health claims for cooking oils and vegetable oil spreads. Bureau of Economics Working Paper No. 288, Federal Trade Commission, Washington, DC.
29. Reiffen D., Ward M.R. (2005). Generic drug industry dynamics. Review of Economics and Statistics 87(1): 37-49
30. Rubinfeld D., Cooter R. (1989). Economic analysis of legal disputes and their resolution. Journal of Economic Literature 23(3): 435-463
31. Shapiro C. (2003). Antitrust limits to patent settlements. RAND Journal of Economics 34(2): 391-411
32. Wiggins S.N., Maness R. (2004). Price competition in pharmaceuticals: The case of anti-infectives. Economic Inquiry 42(2): 247-263
33. Willig R.D., Bigelow J. (2004). Antitrust policy toward agreements that settle patent litigation. Antitrust Bulletin 49(3): 655-698